China's Innovative Drug Sector Booms on Commercialization and Global Deals, Says Brokerage

China's innovative drug sector is in a high-growth phase, propelled by the successful commercialization of new therapies and a wave of international out-licensing agreements, according to a recent research note from China Galaxy Securities. The brokerage stated that these factors are creating significant long-term growth opportunities and driving a revaluation of companies in the space.

A Tale of Two Sectors

Financial results from the first half of the year reveal a stark divergence within China's broader pharmaceutical industry. While listed companies posted modest overall revenue growth of 3.3%, net profit excluding non-recurring items surged by 29.2%, according to the report.

China Galaxy Securities attributes this margin expansion primarily to the high-growth innovative drug segment. Key drivers included better-than-expected orders for Contract Research, Development, and Manufacturing Organizations (CXOs), revenue recognition from overseas licensing deals, and the sales ramp-up of new drugs. In contrast, traditional pharmaceuticals, vaccines, and blood products continued to face pressure.

Innovation Drives Financial Performance

The report highlights that the commercial success of new drugs and a boom in global partnerships are significantly boosting the top and bottom lines for innovators. In the first half of the year, total out-licensing transactions by Chinese drugmakers reached nearly $100 billion, with upfront and milestone payments providing a substantial lift to revenue and profits.

Ad

This trend is reflected in the performance of representative innovative drug companies listed on the A-share and H-share markets, which saw their revenues grow by 50.11% and 40.71%, respectively. The brokerage noted that several of these firms have achieved profitability while continuing to invest heavily in research and development.

Outlook and Key Risks

Despite some operational weaknesses in the broader industry, such as slower hospital payments and rising inventory levels, China Galaxy Securities maintains a positive long-term outlook on innovation-focused sub-sectors. The firm recommends focusing on companies with Best-in-Class (BIC) and First-in-Class (FIC) pipelines, the CXO and life sciences supply chain, and medical device exporters.

The report also identified several risks for investors to monitor, including:

• Macroeconomic pressure impacting healthcare spending.
• Unfavorable changes to national health insurance reimbursement policies.
• Geopolitical tensions that could disrupt global orders.
• Deeper-than-expected price cuts from centralized government procurement programs.